Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 4: Afatinib in Advanced NSCLC
NCT00711594Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose, Objective Tumor Response up to 41.3 months and 1 more. Started Apr 2008; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00711594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711594.